公开(公告)号：US20240311038A1

公开(公告)日：2024-09-19

申请号：US18406997

申请日：2024-01-08

申请人： University of Central Florida Research Foundation, Inc. ,  Board of Regents, University of Texas System

发明人： Rickard Ewetz ,  Sven Thijssen ,  Sumit Kumar Jha

IPC分类号： G06F3/06

CPC分类号： G06F3/0655 ,  G06F3/0604 ,  G06F3/0653 ,  G06F3/0679

摘要： A system and method for evaluating Boolean functions using in-memory computing comprising a plurality of programmed non-volatile memory devices synthesized in a crossbar design. The evaluation phase of a given Boolean function using the programmed non-volatile memory devices is accomplished using READ operations only.

公开(公告)号：US10329326B2

公开(公告)日：2019-06-25

申请号：US15263028

申请日：2016-09-12

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  INTEZYNE TECHNOLOGIES INC. ,  ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA ,  BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

发明人： Robert J. Gillies ,  David L. Morse ,  Natalie M. Barkey ,  Kevin N. Sill ,  Josef Vagner ,  Narges K. Tafreshi ,  Jonathan L. Sessler ,  Christian Preihs ,  Victor J. Hruby

IPC分类号： A61K38/00 ,  C07K5/117 ,  C07K14/68 ,  A61K49/00 ,  A61K49/10 ,  A61K49/18 ,  C07K7/08 ,  C07K14/72 ,  A61K47/64 ,  A61K47/69 ,  A61K38/34

摘要： The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

公开(公告)号：US20180065089A1

公开(公告)日：2018-03-08

申请号：US15258493

申请日：2016-09-07

申请人： Purnendu K. Dasgupta ,  Weixiong Huang

发明人： Purnendu K. Dasgupta ,  Weixiong Huang

IPC分类号： B01D61/48 ,  B01D15/36 ,  B01D15/24 ,  G01N30/96

摘要： An electrodialytic device for ion chromatography, including aspects functioning as an eluent suppressor device and aspects functioning as an eluent generator device. In general, the device includes a monolithic block of ionomeric polymer material having (1) a first channel with an inlet port, an outlet port, and an active length of exposed polymer material disposed therebetween, (2) a second channel having an inlet port, an outlet port, and an active length of exposed polymer material disposed therebetween, (3) a first and second at-least-partially exposed electrodes positioned in electrical communication with the second channel, with the second electrode disposed, at least in part, across the second channel from the first electrode. A current flowing between the electrodes will drive an electrodialytic migration of ions between the active lengths, from an eluent stream in the case of a suppression device or into an eluent stream in the case of a generator device.

公开(公告)号：US09353094B2

公开(公告)日：2016-05-31

申请号：US14639501

申请日：2015-03-05

申请人： BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA ,  THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

发明人： Amarnath Natarajan ,  Qianyi Chen ,  Vashti C. Bryant ,  Rajkumar Rajule

IPC分类号： C07D241/44 ,  C07D409/14 ,  C07D241/42 ,  C07D405/04 ,  C07D405/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04

CPC分类号： C07D409/14 ,  C07D241/42 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/04 ,  C07D405/14 ,  C07D471/04

摘要： Disclosed herein are compounds of formula (I) and methods of inhibiting IKKβ and the NF-κB signaling and mTOR pathways.

摘要翻译： 本文公开了式（I）的化合物和抑制IKK和bgr的方法; 和NF-κB信号通路和mTOR通路。

公开(公告)号：US09216983B2

公开(公告)日：2015-12-22

申请号：US12339905

申请日：2008-12-19

申请人： Margaret Phillips ,  Pradipsinh K. Rathod ,  Ramesh Gujjar ,  Alka Marwaha ,  Susan A. Charman

发明人： Margaret Phillips ,  Pradipsinh K. Rathod ,  Ramesh Gujjar ,  Alka Marwaha ,  Susan A. Charman

IPC分类号： C07D487/04 ,  C07D473/34 ,  A61K31/519

CPC分类号： C07D487/04 ,  C07D473/34

摘要： Compounds according to Formula I, Formula II, Formula III, Formula V, Formula VI, or to Formula VII, and pharmaceutical compositions of compounds that conform to Formula IV or Formula VIII: where R1 through R33 are prescribed, selectively inhibit P. falciparum dihydroorotate dehydrogenase. Accordingly, a method for preventing and treating malaria attaches to such compounds, as well as to pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, and prodrugs thereof.

摘要翻译： 根据式I，式II，式III，式V，式VI或式VII的化合物和符合式IV或式VIII的化合物的药物组合物：其中R1至R33被规定为选择性抑制恶性疟原虫二氢乳清酸 脱氢酶。 因此，用于预防和治疗疟疾的方法附着于这些化合物，以及其药学上可接受的盐，溶剂合物，立体异构体，互变异构体和前药。

公开(公告)号：US08993758B2

公开(公告)日：2015-03-31

申请号：US13883026

申请日：2011-11-22

申请人： Amarnath Natarajan ,  Qianyi Chen ,  Vashti C. Bryant ,  Rajkumar Rajule

发明人： Amarnath Natarajan ,  Qianyi Chen ,  Vashti C. Bryant ,  Rajkumar Rajule

IPC分类号： C07D241/40 ,  C07D241/42 ,  C07D241/44 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04

CPC分类号： C07D409/14 ,  C07D241/42 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/04 ,  C07D405/14 ,  C07D471/04

摘要： Disclosed herein are compounds of formula (I) and methods of inhibiting IKKβ and the NF-κB signaling and mTOR pathways.

摘要翻译： 本文公开了式（I）的化合物和抑制IKK和bgr的方法; 和NF-κB信号通路和mTOR通路。

公开(公告)号：US20140378435A1

公开(公告)日：2014-12-25

申请号：US14479952

申请日：2014-09-08

申请人： Robert A. Davey ,  Andrey A. Kolokoltsov ,  Mohammad F. Saeed

发明人： Robert A. Davey ,  Andrey A. Kolokoltsov ,  Mohammad F. Saeed

IPC分类号： A61K31/554 ,  A61K31/145 ,  A61K31/435 ,  A61K31/4745

CPC分类号： A61K31/554 ,  A61K31/18 ,  A61K31/277 ,  A61K31/366 ,  A61K31/435 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/5377 ,  A61K31/713 ,  A61K33/00

摘要： The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.

摘要翻译： 本发明公开了治疗由病毒感染引起的感染的方法。 这种方法包括在基因或蛋白质水平上阻断PI3激酶途径或钙相关途径。 本文还公开了可用于治疗火山病毒感染的化合物。

公开(公告)号：US08889743B2

公开(公告)日：2014-11-18

申请号：US12653916

申请日：2009-12-21

申请人： Robert A. Davey ,  Andrey A. Kolokoltsov ,  Mohammad F. Saeed

发明人： Robert A. Davey ,  Andrey A. Kolokoltsov ,  Mohammad F. Saeed

IPC分类号： A61K31/135 ,  A61K31/18 ,  A61K31/277 ,  A61K31/713 ,  A61K31/4741 ,  A61K31/366 ,  A61K31/554 ,  A61K33/00 ,  A61K31/435 ,  A61K31/5377

CPC分类号： A61K31/554 ,  A61K31/18 ,  A61K31/277 ,  A61K31/366 ,  A61K31/435 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/5377 ,  A61K31/713 ,  A61K33/00

摘要： The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.

摘要翻译： 本发明公开了治疗由病毒感染引起的感染的方法。 这种方法包括在基因或蛋白质水平上阻断PI3激酶途径或钙相关途径。 本文还公开了可用于治疗火山病毒感染的化合物。

公开(公告)号：US20140239525A1

公开(公告)日：2014-08-28

申请号：US14127019

申请日：2012-06-18

申请人： Jason Thomas McConville ,  Thiago Cordoso Carvalho ,  Niven Rajin Narain ,  John Patrick McCook

发明人： Jason Thomas McConville ,  Thiago Cordoso Carvalho ,  Niven Rajin Narain ,  John Patrick McCook

IPC分类号： A61K9/12 ,  G01N15/02

CPC分类号： A61K9/12 ,  A61K9/0078 ,  A61K9/127 ,  A61K31/122 ,  G01N15/0205 ,  G01N15/0211 ,  G01N2015/0038 ,  Y10T29/49716

摘要： Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQIO) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output.

摘要翻译： 可吸入药物组合物可以包括颗粒的水性分散体，包括适于连续雾化的疏水性生物活性剂（例如CoQIO）。 由于其化学组成和制造方法，药物组合物显示出特征性的物理化学性质，其提供有利的气溶胶传播和输出。

公开(公告)号：US08486391B2

公开(公告)日：2013-07-16

申请号：US11329293

申请日：2006-01-10

申请人： Philip E. Thorpe ,  Sophia Ran

发明人： Philip E. Thorpe ,  Sophia Ran

IPC分类号： A61K39/00

CPC分类号： A61K39/39558 ,  A61K38/00 ,  A61K45/06 ,  A61K47/6849 ,  A61K49/04 ,  A61K49/16 ,  A61K51/1027 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2836 ,  C07K2319/74

摘要： Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

摘要翻译： 披露了令人惊奇的发现，即氨基磷脂如磷脂酰丝氨酸和磷脂酰乙醇胺是稳定的，特异性标记可在肿瘤血管的腔表面上接近，并且单独给予抗氨基磷脂抗体足以诱导血栓形成，肿瘤坏死和肿瘤 体内回归 因此，本发明提供了用于特异性破坏肿瘤血管和用于治疗实体瘤的基于抗氨基磷脂抗体的方法和组合物。 尽管提供了各种抗体缀合物和组合，但是由于方法的简单性和有效性，使用裸体或非共轭抗磷脂酰丝氨酸抗体是本发明的特别重要的方面。